Daniel S. Stein

4.0k total citations
92 papers, 3.0k citations indexed

About

Daniel S. Stein is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Daniel S. Stein has authored 92 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Infectious Diseases, 36 papers in Virology and 36 papers in Epidemiology. Recurrent topics in Daniel S. Stein's work include HIV/AIDS drug development and treatment (44 papers), HIV Research and Treatment (36 papers) and Pneumocystis jirovecii pneumonia detection and treatment (21 papers). Daniel S. Stein is often cited by papers focused on HIV/AIDS drug development and treatment (44 papers), HIV Research and Treatment (36 papers) and Pneumocystis jirovecii pneumonia detection and treatment (21 papers). Daniel S. Stein collaborates with scholars based in United States, Switzerland and United Kingdom. Daniel S. Stein's co-authors include Yu Lou, Brian M. Sadler, George L. Drusano, John A. Bilello, Kenrad E. Nelson, Katy H. P. Moore, James A. McDowell, Sandra L. Preston, Catherine Gillotin and Gregory E. Chittick and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and Gastroenterology.

In The Last Decade

Daniel S. Stein

91 papers receiving 2.9k citations

Peers

Countries citing papers authored by Daniel S. Stein

Since Specialization

Citations

This map shows the geographic impact of Daniel S. Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel S. Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel S. Stein more than expected).

Fields of papers citing papers by Daniel S. Stein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel S. Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel S. Stein. The network helps show where Daniel S. Stein may publish in the future.

Co-authorship network of co-authors of Daniel S. Stein

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel S. Stein. A scholar is included among the top collaborators of Daniel S. Stein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel S. Stein. Daniel S. Stein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine 2018 ·Malaria Journal ·F. Joel Leong, Jay Prakash Jain, (unknown), (unknown), Daniel S. Stein	16
2	Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem®) for bioequivalence in a randomized, open-label, two-period study 2013 ·Malaria Journal ·Gilbert Lefèvre, (unknown), Jay Prakash Jain, (unknown), Yi Cheng, (unknown), Daniel S. Stein	11
3	Population Pharmacokinetics and Exposure‐Response of Albinterferon Alfa‐2b 2011 ·The Journal of Clinical Pharmacology ·Matthew M. Riggs, (unknown), James A. Rogers, Marc R. Gastonguay, G. Mani Subramanian, Cecil Chen, Matt Devalaraja, A. Corey, Haiying Sun, (unknown), Daniel S. Stein	5
4	Single-Dose Safety and Pharmacokinetics of Brecanavir, a Novel Human Immunodeficiency Virus Protease Inhibitor 2006 ·Antimicrobial Agents and Chemotherapy ·Susan L. Ford, Y. Sunila Reddy, (unknown), Sharon C. Murray, P. Fernandez, Daniel S. Stein, Mark Johnson	17
5	Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers 2004 ·AIDS ·Mary Beth Wire, Charles H. Ballow, Sandra L. Preston, Craig W. Hendrix, Peter J. Piliero, Yu Lou, Daniel S. Stein	29
6	Metabolic Disposition and Pharmacokinetics of [¹⁴C]‐Amprenavir, a Human Immunodeficiency Virus Type 1 (HIV‐1) Protease Inhibitor, Administered As a Single Oral Dose to Healthy Male Subjects 2001 ·The Journal of Clinical Pharmacology ·Brian M. Sadler, Gregory E. Chittick, Ronald E. Polk, Douglas Slain, Thomas M. Kerkering, Scott D. Studenberg, Yu Lou, Katy H. P. Moore, Joseph L. Woolley, Daniel S. Stein	16
7	The Safety and Efficacy of Granulocyte‐Macrophage Colony‐Stimulating Factor (Sargramostim) Added to Indinavir‐ or Ritonavir‐Based Antiretroviral Therapy: A Randomized Double‐Blind, Placebo‐Controlled Trial 1999 ·The Journal of Infectious Diseases ·Gail Skowron, Daniel S. Stein, George L. Drusano, Kathleen Melbourne, John A. Bilello, Dennis J. Mikolich, Khurram Rana, Jan M. Agosti, (unknown), James B. Whitmore, M. Jean Gilbert	22
8	Soluble Tumor Necrosis Factor- Receptor Type II (sTNF RII) Correlates with Human Immunodeficiency Virus (HIV) RNA Copy Number in HIV-Infected Patients 1996 ·The Journal of Infectious Diseases ·John A. Bilello, Kathleen A. Stellrecht, George L. Drusano, Daniel S. Stein	43
9	A Comparison of Immediate with Deferred Zidovudine Therapy for Asymptomatic HIV-Infected Adults with CD4 Cell Counts of 500 or More per Cubic Millimeter 1995 ·New England Journal of Medicine ·Paul A. Volberding, Stephen W. Lagakos, (unknown), Daniel S. Stein, James F. Rooney, (unknown), Margaret A. Fischl, Ann C. Collier, John Phair, Martin Hirsch, William D. Hardy, Henry H. Balfour, Richard C. Reichman	88
10	Within-Subject Variation in CD4 Lymphocyte Count in Asymptomatic Human Immunodeficiency Virus Infection: Implications for Patient Monitoring 1994 ·The Journal of Infectious Diseases ·Michael D. Hughes, Daniel S. Stein, Holly Gundacker, Fred Valentine, John Phair, Paul A. Volberding	94
11	The amino-terminal one-third of pseudorabies virus glycoprotein gIII contains a functional attachment domain, but this domain is not required for the efficient penetration of Vero cells 1993 ·Journal of Virology ·Shannon Flynn, (unknown), Daniel S. Stein, (unknown), Patrick J. Ryan	23
12	Hepatomegaly with severe steatosis in HIV-seropositive patients 1993 ·AIDS ·Joel Freiman, (unknown), (unknown), Daniel S. Stein	114
13	Immune-Based Therapeutics: Scientific Rationale and the Promising Approaches to the Treatment of the Human Immunodeficiency Virus-Infected Individual 1993 ·Clinical Infectious Diseases ·Daniel S. Stein, Joseph Timpone, Jeremy D. Gradon, Jonathan Kagan, S M Schnittman	28
14	The hemolysin/bacteriocin produced by enterococci is a marker of pathogenicity 1992 ·Diagnostic Microbiology and Infectious Disease ·Claudia R. Libertin, (unknown), Daniel S. Stein	32
15	Current Status of HIV Therapy 1992 ·Hospital Practice ·Daniel F. Hoth, Maureen Myers, Daniel S. Stein	2
16	Pulmonary Manifestations of Acquired Immunodeficiency Syndrome 1992 ·Clinical Infectious Diseases ·G. Umberto Meduri, Daniel S. Stein	53
17	Pyogenic Hepatic Abscess and Septic Pulmonary Emboli Associated With Klebsiella ozaenae Bacteremia 1992 ·Southern Medical Journal ·Pallabita Chowdhury, Daniel S. Stein	12
18	Cavitary Pneumocystis carinii Pneumonia in Patients Receiving Aerosol Pentamidine Prophylaxis 1991 ·Southern Medical Journal ·Daniel S. Stein, J. John Weems	6
19	Enzymatic extraction and spectral analysis of the chromophore from cell walls of nutritionally deficient streptococci 1989 ·Journal of Clinical Microbiology ·Daniel S. Stein, Claudia R. Libertin	4
20	Time kill curve analysis of vancomycin and rifampin alone and in combination against nine strains of nutritionally deficient streptococci 1988 ·Diagnostic Microbiology and Infectious Disease ·Daniel S. Stein, Claudia R. Libertin	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact